GET DAILY SIGNALSAclarion (ACON): Applying AI and Biomarkers to Chronic Low Back Pain
Key Takeaways
- Aclarion, Inc. operates as a commercial-stage healthcare technology firm that combines Magnetic Resonance Spectroscopy (MRS) with its own AI algorithms to assist physicians in identifying the origin of chronic low back pain.
- Its primary offering, Nociscan, is a cloud-based software-as-a-service platform that processes MRI spectroscopy information to flag whether a spinal disc could be contributing to a patient’s pain.
- Headquartered in Broomfield, Colorado, the company lists on Nasdaq under the ticker ACON.
- Aclarion remains an early-stage, pre-profitability enterprise centered on clinical validation, expanding reimbursement, and increasing platform adoption.
Company Overview
Aclarion, Inc. sits at the crossroads of medical imaging, biomarkers, and artificial intelligence. Its goal is to supply physicians with objective biochemical information that can refine the diagnosis and treatment of chronic low back pain, a widespread condition that has long proved challenging to pinpoint accurately. I follow ACON as a modest, early-stage participant working to establish a scalable, software-focused presence in the sizable spine-care sector.
The Nociscan Platform and Business Model
Founded in 2008 and formerly known as Nocimed, Inc., Aclarion is based in Broomfield, Colorado, and trades on Nasdaq under ACON, with warrants listed separately as ACONW. Its flagship product, Nociscan, is a cloud-based SaaS platform backed by clinical evidence. The system receives MRS data from standard MRI machines for each lumbar disc under review. Proprietary signal-processing methods then extract and measure chemical biomarkers linked to disc pain, after which Aclarion’s algorithms assess whether a given disc may be a pain source. When paired with other diagnostic methods, the company notes that Nociscan can provide added clarity for treatment planning, including surgical choices.
Rather than selling imaging hardware, Aclarion focuses on software and data services. Because the platform works with existing MRI equipment, it is built to fit into current radiology and spine-care processes. Revenue is expected to stem mainly from clinical use of Nociscan at participating sites, backed by ongoing efforts to obtain insurance coverage in the United States and the United Kingdom. The company targets physicians, imaging centers, and health systems treating persistent low back pain, with its edge resting on a proprietary biomarker library, intellectual property, and accumulating clinical data.
Investor Perspective on ACON
Interest in ACON largely tracks the scale of the chronic low back pain market and the prospect of a software-based diagnostic becoming a standard tool in spine-care decisions. In contrast to hardware manufacturers that incur per-unit production costs, Aclarion’s SaaS model holds the potential for attractive margins and scalability as scan volumes rise. I also checked this using Tickeron’s AI Screener to compare the stock with others in the sector.
Longer-term catalysts include further clinical validation through trials and real-world studies, wider compatibility with MRI systems, and progress on payer reimbursement. The company has noted rising scan volumes as it advances from initial commercial steps toward broader use, while also reinforcing its intellectual property around AI and biomarker methods. Financially, Aclarion is still very early-stage, with limited revenue and ongoing costs tied to commercialization and development. Investors typically assess it on technology strength, market opportunity, and cash runway rather than near-term earnings.
Key Risks to Consider
Investing in Aclarion involves risks typical of early-stage healthcare technology companies. The firm is not yet profitable and posts only modest revenue, so it may continue to depend on capital raises and its cash position to support operations. Additional factors include the need for wider clinical adoption and reimbursement; without payer backing, access and revenue growth could stay constrained. Competition from established diagnostic and imaging firms is another consideration, as is the requirement to keep demonstrating clinical utility through studies. Regulatory, market, and technological factors add further uncertainty, and shareholders should note the potential for significant price volatility and dilution from future equity offerings.
Research Tools I Use
When reviewing opportunities such as ACON, I often turn to Tickeron’s AI Screener to filter across technical indicators, fundamentals, volatility, trends, and AI signals. The platform lets me quickly surface ideas that match specific strategies and build a more informed watchlist without sifting through data manually.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
ACON's Stochastic Oscillator is remaining in oversold zone for 6 days
The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where ACON's RSI Indicator exited the oversold zone, 30 of 35 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 86%.
Following a +10.97% 3-day Advance, the price is estimated to grow further. Considering data from situations where ACON advanced for three days, in 144 of 173 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
ACON may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ACON as a result. In 84 of 92 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
The Moving Average Convergence Divergence Histogram (MACD) for ACON turned negative on November 03, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 43 similar instances when the indicator turned negative. In 40 of the 43 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
The 10-day moving average for ACON crossed bearishly below the 50-day moving average on October 07, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ACON declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for ACON entered a downward trend on November 11, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 13 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 71 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.281) is normal, around the industry mean (4.477). P/E Ratio (-0.239) is within average values for comparable stocks, (13.414). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.133). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. ACON's P/S Ratio (45.662) is very high in comparison to the industry average of (6.065).
The Tickeron Price Growth Rating for this company is 87 (best 1 - 100 worst), indicating slightly worse than average price growth. ACON’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ACON’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 97, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry ServicestotheHealthIndustry
Advertisement